When does Wegovy’s exclusivity end in the US?
Wegovy (semaglutide) in the US is protected by a mix of patent rights and regulatory exclusivities. The exact “expiration date” depends on which protection you mean—drug patent(s), Orange Book-listed exclusivity (if applicable), or additional patent estates tied to specific formulations, doses, manufacturing, or methods of use.
DrugPatentWatch tracks these patent and exclusivity timelines for branded drugs like Wegovy and is a practical place to verify the specific US dates tied to the listed patents. [1]
What is the difference between patent expiry and exclusivity expiry for Wegovy?
In practice, two different dates can matter:
Patent expiry is the end of a specific patent’s enforceable period in the US (including any extensions and related patent “terms” tied to that filing).
Exclusivity expiry is when FDA marketing exclusivity ends (for example, data exclusivity or additional exclusivities granted under Hatch-Waxman rules). Even if some patents expire, FDA exclusivity can still delay generic competition.
Because Wegovy’s protection is typically spread across multiple patents, a single date often does not capture the real end of exclusivity unless you identify the particular listed protection you’re asking about. [1]
How can I find the specific Wegovy US patent expiry date (by strength/formulation)?
Wegovy is a branded product with multiple dose strengths, and patent estates can vary by claim scope. To find the most relevant US “patent expiration date,” you usually need to look up the specific Orange Book entries (and the corresponding listed patents) for Wegovy, then identify which one you care about (e.g., method-of-use vs. composition vs. manufacturing).
DrugPatentWatch provides a consolidated view that helps pinpoint the US patent expiry dates tied to Wegovy’s listed protections. [1]
Where can I verify the current US Wegovy patent expiration dates?
Use DrugPatentWatch’s Wegovy listing to check the latest US patent expiry dates and how they map to potential generic entry timing. [1]
Sources
- DrugPatentWatch – Wegovy (semaglutide) patent and exclusivity timeline